{"nctId":"NCT00982228","briefTitle":"Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes","startDateStruct":{"date":"2009-09-01","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":629,"armGroups":[{"label":"IDeg OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin aspart"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes mellitus for at least 12 months\n* Current treatment with any basal bolus insulin for at least 12 months\n* HbA1c below or equal to 10.0%\n* BMI (Body Mass Index) below or equal to 35.0 kg/m\\^2\n* For the extension trial only: Completion of the 52 week treatment period in trial NN1250-3583 (NCT00982228)\n\nExclusion Criteria:\n\n* Use of any other antidiabetic drug than insulin within the last 3 months\n* Cardiovascular disease within the last 6 months\n* Uncontrolled treated/untreated severe hypertension\n* Recurrent severe hypoglycemia or hypoglycemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements\n* Cancer and medical history of cancer","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","description":"Change from baseline in HbA1c after 52 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"0.73"},{"groupId":"OG001","value":"-0.39","spread":"0.84"}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)","description":"Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"383","spread":null},{"groupId":"OG001","value":"374","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"256","spread":null},{"groupId":"OG001","value":"242","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3750","spread":null},{"groupId":"OG001","value":"3743","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"390","spread":null},{"groupId":"OG001","value":"532","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Cross-reacting Antibodies to Human Insulin","description":"The unit for measuring antibody levels is amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture (%B/T). Samples were taken before 1st dosing and after a 1-week wash-out period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"15.6"},{"groupId":"OG001","value":"11.0","spread":"16.0"}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment","description":"Change from baseline in HbA1c after 104 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.75"},{"groupId":"OG001","value":"-0.24","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 104 of Treatment","description":"Mean of 9-point self-measured plasma glucose profile (SMPG) after 104 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"2.2"},{"groupId":"OG001","value":"8.1","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4254","spread":null},{"groupId":"OG001","value":"4018","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"441","spread":null},{"groupId":"OG001","value":"586","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52","description":"Mean of 9-point self-measured plasma glucose profile (SMPG) after 52 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"2.3"},{"groupId":"OG001","value":"8.3","spread":"2.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":472},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Influenza"]}}}